<

NA-831 catalyzes the adult neurogenesis



Watch the video on youtube: https://www.youtube.com/watch?v=RYCW3SNzpTY

For further information neurogenesis, please contact us by completing an Online Contact Form. Thank you.
Learn more

NA-831 regenerates new neurons to improve cognition functions

The hippocampus is essential for learning and memory formation and one of the first brain regions affected in the development of Alzheimer’s disease (AD). In the hippocampus, new neurons are generated throughout life via a process called adult hippocampal neurogenesis (AHN).

In mild cognitive impairment (MCI) and mild to moderate AD (early AD), AHN is reduced suggesting that AHN impairment compromises hippocampal function. Accordingly, augmenting AHN could help prevent or slow cognitive decline in MCI and early AD.

NA-831 restores neurogenesis by activating synaptic AMPA receptors, and increases the expression of BDNF (brain derived neurotrophic factor). BDNF is crucial in synaptic plasticity, learning and memory formation in the hippocampus.


Learn more
Traneurocin NA-831 bottle
Traneurocin (NA-831)

Traneuroci™ or NA-831 provides neuroprotection and catalyzing the regeneration of new neurons. Oral 30 mg per day for patients with early onset of Alzheimer’s Disease. NA-831 is manufactured by NeuroActiva, a subsidiary of Biomed. 

Learn more
Biomedigital
Biomedigital

Biomed Digital is harnessing the power of wearable technology and machine learning to create a digital phenotype that helps clinicians to diagnose early onset of Alzheimer’s disease.

Learn more
clinical trials
Research & Clinical Trials

Biomed is conducting Phase 3 clinical trials of NA-831 for the treatment and prevention of Alzheimer’s disease. We also conduct Phase 2/3 trials of NA-831 in combination with Atazanavir, Remdesivir, and Dexaneurosone and Ivermectin for treating Covid-19

Learn more
NA-704 injectable drug
NA-704

Vineurocin (NA-704) is an injectable drug, to regenerate new neurons, and reducting of muscular spasticity, a strong candidate for treatment of Alzheimer’s disease and Parkinson’s disease. NA-704 can be administered with the MICROS. NA-704 is in the Phase 1 safety studies.

Learn more
MICROS
MICROS™ Infusion System

The MICROS is a controlled release infusion system which has been approved for marketing in the US. It is used for intravenous administration of injectable drugs. NA-704 can be administerd via the MICROS at home care settings. It is an accurate, safe and cost effective drug delivery system.

Learn more
drug mixture
Combination Therapy-NA-831

Combination therapy of NA-831 and an antiviral drugs such as Atazanavir, Remdesivir (Gilead Sciences) and anti-inflammatory such as Dexaneurosone and Ivermectin can enhance the effectiveness of the treatment of Covid-19.

Learn more
Neurogenesis

Neurogenesis and
Alzheimer's Disease

NA-831 restores neurogenesis by increasing the expression of BDNF (brain derived neurotrophic factor). NA-831 serves as a catalyst to restore neurogenesis in Alzheimer’s patients, with higher numbers of neuroblasts leading to improved cognitive function. Learn more

Covid-19

and Alzheimer's disease

Covid-19 viruses can cross the blood brain barrier via infected vascular endothelial cells and/or infected leukocytes to damage the central nervous system.
As a neuroprotective agent, NA-831 can protect the brain from Covid-19 infection. Learn more
Covid-19- brain